Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.

Trial Details

NCT ID
NCT06613217
Phase
PHASE1
Sponsor
Pacylex Pharmaceuticals
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • zelenirstat
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • The following inclusion criteria apply to ALL (dose escalation and dose expansion) patients:
  • Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained before any study-specific …
  • Male or female patients aged ≥ 18 years
  • A diagnosis of AML as per 2016 WHO classification (Arber et al, 2016)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →